National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2013 (No. 8) (No. PB 39 of 2013)

Link to law: https://www.comlaw.gov.au/Details/F2013L01096

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
PB 39 of 2013
National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2013
(No. 8)
National Health Act 1953
I, Adriana Platona, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under sections 84AF, 84AK, 85, 85A, 88 and 99AEH of the National Health Act 1953.
Dated                                          18 June 2013
 
 
 
 
 
 
 
 
 
 
 
ADRIANA PLATONA
Assistant Secretary
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health and Ageing
 
1          Name of Instrument
            (1)        This Instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2013 (No. 8).
            (2)        This Instrument may also be cited as PB 39 of 2013.
2          Commencement
This Instrument commences on 1 July 2013.
3          Amendment of National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012)
            Schedule 1 amends the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012).
Schedule 1     Amendments
 
[1]           Schedule 1, entry for Rosuvastatin in the form Tablet 5 mg (as calcium)
(a)      omit:
 
 
 
Cavstat
AF
MP
C1540 C3047 C4225 C4228
P1540 P4228
30
5
30
 
 

 
 
 
 
 
NP
C1540 C4228
 
30
5
30
 
 

(b)      omit:
 
 
 
Rosuvastatin GH
GQ
MP
C1540 C3047 C4225 C4228
P1540 P4228
30
5
30
 
 

 
 
 
 
 
NP
C1540 C4228
 
30
5
30
 
 

(c)      omit:
 
 
 
Cavstat
AF
MP
C1540 C3047 C4225 C4228
P3047 P4225
30
11
30
 
 
(d)      omit:
 
 
 
Rosuvastatin GH
GQ
MP
C1540 C3047 C4225 C4228
P3047 P4225
30
11
30
 
 
[2]           Schedule 1, entry for Rosuvastatin in the form Tablet 10 mg (as calcium)
(a)      omit:
 
 
 
Cavstat
AF
MP
C1540 C3047 C4225 C4228
P1540 P4228
30
5
30
 
 

 
 
 
 
 
NP
C1540 C4228
 
30
5
30
 
 

(b)      omit:
 
 
 
Rosuvastatin GH
GQ
MP
C1540 C3047 C4225 C4228
P1540 P4228
30
5
30
 
 

 
 
 
 
 
NP
C1540 C4228
 
30
5
30
 
 

(c)      omit:
 
 
 
Cavstat
AF
MP
C1540 C3047 C4225 C4228
P3047 P4225
30
11
30
 
 
(d)      omit:
 
 
 
Rosuvastatin GH
GQ
MP
C1540 C3047 C4225 C4228
P3047 P4225
30
11
30
 
 
[3]           Schedule 1, entry for Rosuvastatin in the form Tablet 20 mg (as calcium)
(a)      omit:
 
 
 
Cavstat
AF
MP
C1540 C3047 C4225 C4227
P1540 P4227
30
5
30
 
 

 
 
 
 
 
NP
C1540 C4227
 
30
5
30
 
 

(b)      omit:
 
 
 
Rosuvastatin GH
GQ
MP
C1540 C3047 C4225 C4227
P1540 P4227
30
5
30
 
 

 
 
 
 
 
NP
C1540 C4227
 
30
5
30
 
 

(c)      omit:
 
 
 
Cavstat
AF
MP
C1540 C3047 C4225 C4227
P3047 P4225
30
11
30
 
 
(d)      omit:
 
 
 
Rosuvastatin GH
GQ
MP
C1540 C3047 C4225 C4227
P3047 P4225
30
11
30
 
 
[4]           Schedule 1, entry for Rosuvastatin in the form Tablet 40 mg (as calcium)
(a)      omit:
 
 
 
Cavstat
AF
MP
C1540 C3047 C4225 C4226
P1540 P4226
30
5
30
 
 

 
 
 
 
 
NP
C1540 C4226
 
30
5
30
 
 

(b)      omit:
 
 
 
Rosuvastatin GH
GQ
MP
C1540 C3047 C4225 C4226
P1540 P4226
30
5
30
 
 

 
 
 
 
 
NP
C1540 C4226
 
30
5
30
 
 

(c)      omit:
 
 
 
Cavstat
AF
MP
C1540 C3047 C4225 C4226
P3047 P4225
30
11
30
 
 
(d)      omit:
 
 
 
Rosuvastatin GH
GQ
MP
C1540 C3047 C4225 C4226
P3047 P4225
30
11
30
 
 
­­­­­­­­­­­­